1mg/mL (2.5ml)
Trade Name
Columvi
Concentrate for Solution for Infusion
Request Type
Registration
Drug Type
Biological Drug
Approval Date
SFDA Approved Use
Glofitamab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.